{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T08:16:45Z","timestamp":1770452205567,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T00:00:00Z","timestamp":1543276800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11102-018-0926-y","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T04:22:17Z","timestamp":1543292537000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"Federico","family":"Gatto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marica","family":"Arvigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Amar\u00f9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Campana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Cocchiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mara","family":"Boschetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,27]]},"reference":[{"issue":"24","key":"926_CR1","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","volume":"309","author":"S Reichlin","year":"1983","unstructured":"Reichlin S (1983) Somatostatin. N Engl J Med 309(24):1495\u20131501. \n                    https:\/\/doi.org\/10.1056\/NEJM198312153092406","journal-title":"N Engl J Med"},{"issue":"3","key":"926_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"YC Patel","year":"1999","unstructured":"Patel YC (1999) Somatostatin and its receptor family. Front Neuroendocrinol 20(3):157\u2013198. \n                    https:\/\/doi.org\/10.1006\/frne.1999.0183","journal-title":"Front Neuroendocrinol"},{"issue":"7","key":"926_CR3","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1210\/jc.2008-2564","volume":"94","author":"M Duran-Prado","year":"2009","unstructured":"Duran-Prado M, Gahete MD, Martinez-Fuentes AJ, Luque RM, Quintero A, Webb SM, Benito-Lopez P, Leal A, Schulz S, Gracia-Navarro F, Malagon MM, Castano JP (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab 94(7):2634\u20132643. \n                    https:\/\/doi.org\/10.1210\/jc.2008-2564","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"926_CR4","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34(3):228\u2013252. \n                    https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.005","journal-title":"Front Neuroendocrinol"},{"issue":"4","key":"926_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","volume":"70","author":"T Gunther","year":"2018","unstructured":"Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castano JP, Wester HJ, Culler M, Melmed S, Schulz S (2018) International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev 70(4):763\u2013835. \n                    https:\/\/doi.org\/10.1124\/pr.117.015388","journal-title":"Pharmacol Rev"},{"issue":"1","key":"926_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11102-016-0778-2","volume":"20","author":"A Ben-Shlomo","year":"2017","unstructured":"Ben-Shlomo A, Liu NA, Melmed S (2017) Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas. Pituitary 20(1):93\u201399. \n                    https:\/\/doi.org\/10.1007\/s11102-016-0778-2","journal-title":"Pituitary"},{"issue":"2","key":"926_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.pharmthera.2007.06.010","volume":"116","author":"D Cervia","year":"2007","unstructured":"Cervia D, Bagnoli P (2007) An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther 116(2):322\u2013341. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2007.06.010","journal-title":"Pharmacol Ther"},{"issue":"3","key":"926_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","volume":"21","author":"A Ben-Shlomo","year":"2010","unstructured":"Ben-Shlomo A, Melmed S (2010) Pituitary somatostatin receptor signaling. Trends Endocrinol Metab 21(3):123\u2013133. \n                    https:\/\/doi.org\/10.1016\/j.tem.2009.12.003","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"926_CR9","doi-asserted-by":"publisher","first-page":"R223","DOI":"10.1530\/JME-14-0011","volume":"52","author":"D Cuevas-Ramos","year":"2014","unstructured":"Cuevas-Ramos D, Fleseriu M (2014) Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol 52(3):R223\u2013R240. \n                    https:\/\/doi.org\/10.1530\/JME-14-0011","journal-title":"J Mol Endocrinol"},{"issue":"12","key":"926_CR10","doi-asserted-by":"publisher","first-page":"R551","DOI":"10.1530\/ERC-16-0151","volume":"23","author":"K Oberg","year":"2016","unstructured":"Oberg K, Lamberts SW (2016) Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 23(12):R551\u2013R566. \n                    https:\/\/doi.org\/10.1530\/ERC-16-0151","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"926_CR11","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","volume":"31","author":"W Bauer","year":"1982","unstructured":"Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ (1982) Pless: SMS 201\u2013995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31(11):1133\u20131140","journal-title":"Life Sci"},{"issue":"1\u20132","key":"926_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.mce.2007.11.024","volume":"286","author":"A Ben-Shlomo","year":"2008","unstructured":"Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286(1\u20132):192\u2013198. \n                    https:\/\/doi.org\/10.1016\/j.mce.2007.11.024","journal-title":"Mol Cell Endocrinol"},{"issue":"11","key":"926_CR13","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine S (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. \n                    https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"926_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, Strasburger CJ, Luger A, Clemmons DR, Giustina A (2018) A Consensus Statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. \n                    https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"926_CR15","doi-asserted-by":"publisher","first-page":"E1880","DOI":"10.1210\/jc.2013-1987","volume":"98","author":"R Pas van der","year":"2013","unstructured":"van der Pas R, Feelders RA, Gatto F, de Bruin C, Pereira AM, van Koetsveld PM, Sprij-Mooij DM, Waaijers AM, Dogan F, Schulz S, Kros JM, Lamberts SW, Hofland LJ (2013) Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J Clin Endocrinol Metab 98(12):E1880\u2013E1890. \n                    https:\/\/doi.org\/10.1210\/jc.2013-1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"926_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","volume":"24","author":"LJ Hofland","year":"2003","unstructured":"Hofland LJ, Lamberts SW (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24(1):28\u201347. \n                    https:\/\/doi.org\/10.1210\/er.2000-0001","journal-title":"Endocr Rev"},{"issue":"5","key":"926_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1677\/JME-08-0162","volume":"42","author":"D Ferone","year":"2009","unstructured":"Ferone D, Gatto F, Arvigo M, Resmini E, Boschetti M, Teti C, Esposito D, Minuto F (2009) The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol 42(5):361\u2013370. \n                    https:\/\/doi.org\/10.1677\/JME-08-0162","journal-title":"J Mol Endocrinol"},{"key":"926_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2147\/DDDT.S77999","volume":"10","author":"D Cuevas-Ramos","year":"2016","unstructured":"Cuevas-Ramos D, Fleseriu M (2016) Pasireotide: a novel treatment for patients with acromegaly. Drug Des Dev Ther 10:227\u2013239. \n                    https:\/\/doi.org\/10.2147\/DDDT.S77999","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"926_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1210\/jc.2008-1919","volume":"94","author":"S Lesche","year":"2009","unstructured":"Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S (2009) Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J Clin Endocrinol Metab 94(2):654\u2013661. \n                    https:\/\/doi.org\/10.1210\/jc.2008-1919","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"926_CR20","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1210\/me.2010-0398","volume":"25","author":"YJ Kao","year":"2011","unstructured":"Kao YJ, Ghosh M, Schonbrunn A (2011) Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists. Mol Endocrinol 25(6):1040\u20131054. \n                    https:\/\/doi.org\/10.1210\/me.2010-0398","journal-title":"Mol Endocrinol"},{"issue":"1","key":"926_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1210\/me.2009-0321","volume":"24","author":"R Cescato","year":"2010","unstructured":"Cescato R, Loesch KA, Waser B, Macke HR, Rivier JE, Reubi JC, Schonbrunn A (2010) Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol 24(1):240\u2013249. \n                    https:\/\/doi.org\/10.1210\/me.2009-0321","journal-title":"Mol Endocrinol"},{"issue":"2","key":"926_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1210\/me.2009-0315","volume":"24","author":"F Poll","year":"2010","unstructured":"Poll F, Lehmann D, Illing S, Ginj M, Jacobs S, Lupp A, Stumm R, Schulz S (2010) Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24(2):436\u2013446. \n                    https:\/\/doi.org\/10.1210\/me.2009-0315","journal-title":"Mol Endocrinol"},{"issue":"1\u20132","key":"926_CR23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mce.2014.02.009","volume":"387","author":"A Lehmann","year":"2014","unstructured":"Lehmann A, Kliewer A, Schutz D, Nagel F, Stumm R, Schulz S (2014) Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor. Mol Cell Endocrinol 387(1\u20132):44\u201351. \n                    https:\/\/doi.org\/10.1016\/j.mce.2014.02.009","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"926_CR24","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M, Pasireotide CSG (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791\u2013799. \n                    https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"926_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","author":"GK Stalla","year":"1994","unstructured":"Stalla GK, Brockmeier SJ, Renner U, Newton C, Buchfelder M, Stalla J, Muller OA (1994) Octreotide exerts different effects in vivo and in vitro in Cushing\u2019s disease. Eur J Endocrinol 130(2):125\u2013131","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"926_CR26","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1530\/acta.0.1200760","volume":"120","author":"SW Lamberts","year":"1989","unstructured":"Lamberts SW, Uitterlinden P, Klijn JM (1989) The effect of the long-acting somatostatin analogue SMS 201\u2013995 on ACTH secretion in Nelson\u2019s syndrome and Cushing\u2019s disease. Acta Endocrinol 120(6):760\u2013766","journal-title":"Acta Endocrinol"},{"issue":"8 Suppl 1","key":"926_CR27","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0026-0495(96)90091-8","volume":"45","author":"WW Herder de","year":"1996","unstructured":"de Herder WW, Lamberts SW (1996) Is there a role for somatostatin and its analogs in Cushing\u2019s syndrome? Metabolism 45(8 Suppl 1):83\u201385","journal-title":"Metabolism"},{"issue":"10","key":"926_CR28","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide BSG (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"issue":"2","key":"926_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1210\/jc.2012-3126","volume":"98","author":"RA Feelders","year":"2013","unstructured":"Feelders RA, Hofland LJ (2013) Medical treatment of Cushing\u2019s disease. J Clin Endocrinol Metab 98(2):425\u2013438. \n                    https:\/\/doi.org\/10.1210\/jc.2012-3126","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"926_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36(4):385\u2013486. \n                    https:\/\/doi.org\/10.1210\/er.2013-1048","journal-title":"Endocr Rev"},{"issue":"5","key":"926_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707\u2013716","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"926_CR32","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1210\/jc.2003-031319","volume":"89","author":"RD Murray","year":"2004","unstructured":"Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, Melmed S (2004) The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab 89(6):3027\u20133032. \n                    https:\/\/doi.org\/10.1210\/jc.2003-031319","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"926_CR33","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/jc.2003-031344","volume":"89","author":"LJ Hofland","year":"2004","unstructured":"Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577\u20131585. \n                    https:\/\/doi.org\/10.1210\/jc.2003-031344","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"926_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/JOE-16-0332","volume":"231","author":"A Ibanez-Costa","year":"2016","unstructured":"Ibanez-Costa A, Rivero-Cortes E, Vazquez-Borrego MC, Gahete MD, Jimenez-Reina L, Venegas-Moreno E, de la Riva A, Arraez MA, Gonzalez-Molero I, Schmid HA, Maraver-Selfa S, Gavilan-Villarejo I, Garcia-Arnes JA, Japon MA, Soto-Moreno A, Galvez MA, Luque RM, Castano JP (2016) Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. J Endocrinol 231(2):135\u2013145. \n                    https:\/\/doi.org\/10.1530\/JOE-16-0332","journal-title":"J Endocrinol"},{"issue":"6","key":"926_CR35","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F, Feelders RA, Franck SE, van Koetsveld PM, Dogan F, Kros JM, Neggers S, van der Lely AJ, Lamberts SWJ, Ferone D, Hofland LJ (2017) In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab 102(6):2009\u20132018. \n                    https:\/\/doi.org\/10.1210\/jc.2017-00135","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"926_CR36","doi-asserted-by":"publisher","first-page":"R233","DOI":"10.1530\/ERC-10-0334","volume":"18","author":"F Gatto","year":"2011","unstructured":"Gatto F, Hofland LJ (2011) The role of somatostatin and dopamine D2 receptors in endocrine tumors. Endocr Relat Cancer 18(6):R233\u2013R251. \n                    https:\/\/doi.org\/10.1530\/ERC-10-0334","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"926_CR37","doi-asserted-by":"publisher","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmid HA, Schoeffter P, Hoyer D, Cervia D, Taylor JE, Culler MD, Lamberts SW, Hofland LJ (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289(2):E278\u2013E287. \n                    https:\/\/doi.org\/10.1152\/ajpendo.00004.2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"926_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1677\/JME-08-0110","volume":"42","author":"C Bruin de","year":"2009","unstructured":"de Bruin C, Feelders RA, Waaijers AM, van Koetsveld PM, Sprij-Mooij DM, Lamberts SW, Hofland LJ (2009) Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol 42(1):47\u201356. \n                    https:\/\/doi.org\/10.1677\/JME-08-0110","journal-title":"J Mol Endocrinol"},{"issue":"3","key":"926_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000072798","volume":"78","author":"S Park","year":"2003","unstructured":"Park S, Kamegai J, Kineman RD (2003) Role of glucocorticoids in the regulation of pituitary somatostatin receptor subtype (sst1\u2013sst5) mRNA levels: evidence for direct and somatostatin-mediated effects. Neuroendocrinology 78(3):163\u2013175. \n                    https:\/\/doi.org\/10.1159\/000072798","journal-title":"Neuroendocrinology"},{"issue":"4","key":"926_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645\u2013654. \n                    https:\/\/doi.org\/10.1530\/eje.1.01876","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"926_CR41","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, Swearingen B, Hedley-Whyte ET, Stratakis CA, Klibanski A (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91(11):4482\u20134488. \n                    https:\/\/doi.org\/10.1210\/jc.2006-1245","journal-title":"J Clin Endocrinol Metab"},{"issue":"43","key":"926_CR42","doi-asserted-by":"publisher","first-page":"17591","DOI":"10.1073\/pnas.1209411109","volume":"109","author":"RH Oakley","year":"2012","unstructured":"Oakley RH, Revollo J, Cidlowski JA (2012) Glucocorticoids regulate arrestin gene expression and redirect the signaling profile of G protein-coupled receptors. Proc Natl Acad Sci USA 109(43):17591\u201317596. \n                    https:\/\/doi.org\/10.1073\/pnas.1209411109","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"926_CR43","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1210\/jc.2009-1311","volume":"94","author":"A Ben-Shlomo","year":"2009","unstructured":"Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342\u20134350. \n                    https:\/\/doi.org\/10.1210\/jc.2009-1311","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"926_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000327429","volume":"94","author":"V Castillo","year":"2011","unstructured":"Castillo V, Theodoropoulou M, Stalla J, Gallelli MF, Cabrera-Blatter MF, Haedo MR, Labeur M, Schmid HA, Stalla GK, Arzt E (2011) Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing\u2019s disease. Neuroendocrinology 94(2):124\u2013136. \n                    https:\/\/doi.org\/10.1159\/000327429","journal-title":"Neuroendocrinology"},{"issue":"1\u20132","key":"926_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mce.2014.07.001","volume":"394","author":"S Murasawa","year":"2014","unstructured":"Murasawa S, Kageyama K, Sugiyama A, Ishigame N, Niioka K, Suda T, Daimon M (2014) Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo. Mol Cell Endocrinol 394(1\u20132):37\u201346. \n                    https:\/\/doi.org\/10.1016\/j.mce.2014.07.001","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"926_CR46","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1210\/jcem-54-2-286","volume":"54","author":"SW Lamberts","year":"1982","unstructured":"Lamberts SW, de Lange SA, Stefanko SZ (1982) Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing\u2019s disease: differences in the regulation of hormone secretion. J Clin Endocrinol Metab 54(2):286\u2013291. \n                    https:\/\/doi.org\/10.1210\/jcem-54-2-286","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"926_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1530\/EJE-15-0689","volume":"174","author":"K Hayashi","year":"2016","unstructured":"Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H, Fukuhara N, Okada M, Nishioka H, Takeuchi Y, Komada M, Takeshita A, Yamada S (2016) The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease. Eur J Endocrinol 174(2):213\u2013226. \n                    https:\/\/doi.org\/10.1530\/EJE-15-0689","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"926_CR48","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1210\/en.2014-1063","volume":"155","author":"E Peverelli","year":"2014","unstructured":"Peverelli E, Giardino E, Treppiedi D, Vitali E, Cambiaghi V, Locatelli M, Lasio GB, Spada A, Lania AG, Mantovani G (2014) Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology 155(8):2932\u20132941. \n                    https:\/\/doi.org\/10.1210\/en.2014-1063","journal-title":"Endocrinology"},{"issue":"12","key":"926_CR49","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1210\/en.2013-1672","volume":"154","author":"F Gatto","year":"2013","unstructured":"Gatto F, Feelders R, van der Pas R, Kros JM, Dogan F, van Koetsveld PM, van der Lelij AJ, Neggers SJ, Minuto F, de Herder W, Lamberts SW, Ferone D, Hofland LJ (2013) beta-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology 154(12):4715\u20134725. \n                    https:\/\/doi.org\/10.1210\/en.2013-1672","journal-title":"Endocrinology"},{"issue":"2","key":"926_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1530\/EJE-15-0832","volume":"174","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, Giampietro A, Mormando M, Clear AJ, Doglietto F, Anile C, Maira G, Lauriola L, Rindi G, Roncaroli F, Pontecorvi A, Korbonits M, De Marinis L (2016) Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174(2):241\u2013250. \n                    https:\/\/doi.org\/10.1530\/EJE-15-0832","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"926_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1210\/jc.2014-2468","volume":"100","author":"D Cuevas-Ramos","year":"2015","unstructured":"Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100(1):122\u2013131. \n                    https:\/\/doi.org\/10.1210\/jc.2014-2468","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"926_CR52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","volume":"440","author":"M Papotti","year":"2002","unstructured":"Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G (2002) Expression of somatostatin receptor types 1\u20135 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440(5):461\u2013475. \n                    https:\/\/doi.org\/10.1007\/s00428-002-0609-x","journal-title":"Virchows Arch"},{"issue":"1","key":"926_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3275\/8305","volume":"36","author":"LE Wildemberg","year":"2013","unstructured":"Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR (2013) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 36(1):38\u201343. \n                    https:\/\/doi.org\/10.3275\/8305","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"926_CR54","doi-asserted-by":"publisher","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","volume":"98","author":"O Casar-Borota","year":"2013","unstructured":"Casar-Borota O, Heck A, Schulz S, Nesland JM, Ramm-Pettersen J, Lekva T, Alafuzoff I, Bollerslev J (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98(11):E1730\u2013E1739. \n                    https:\/\/doi.org\/10.1210\/jc.2013-2145","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"926_CR55","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","volume":"98","author":"F Gatto","year":"2013","unstructured":"Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW, de Herder WW, Ferone D, Hofland LJ (2013) Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98(1):E66\u2013E71. \n                    https:\/\/doi.org\/10.1210\/jc.2012-2609","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-018-0926-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-018-0926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-018-0926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T19:17:43Z","timestamp":1574795863000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-018-0926-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,27]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1007\/s11102-018-0926-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,27]]},"assertion":[{"value":"27 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FG has been a speaker for Novartis and has participated on advisory boards of Novartis, AMCo Ltd, and IONIS Pharmaceuticals. DF has been a speaker for and participated on advisory boards and received research grants from Novartis, Ipsen and Pfizer. The other Authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}]}}